Ann: Oral Devices and Cannabinoid Sales Update, page-34

First 34 Last

Share
Profile

Follow
MickeyMantle536

933 Posts.

1446

03/06/20

22:42

Post #: 45021258
Share

Originally posted by MickeyMantle536 ↑

Anyone who’s followed IHL for a few years could see the writing on the wall for the devices business, COVID simply accelerated the decision. I spoke to my broker today and he said there was zero cost associated with either the push towards China manufacturing or shuttering this part of the business.

Oils sales appears to be ramping up nicely. If quarterly revenue is increasing significantly without the contribution of the devices business then it should be a great year for penetration into that market and international wholesale supply will increase margins. I think we have an excellent opportunity to be the biggest player in the Australian CBD space.

It makes sense to initiate all these changes now and transition to a Pharmaceutical GICS code. Believe it or not this is important, particularly as the IP develops and potentially attracts interest and capital from other parties who are interested in commercializing a drug in a billion dollar sector, not mouth guards.

Only weeks until stage 1 ARDS results and the OSA and TBI trials to follow. Exciting times for those who are shareholders.

Expand

I love this line from “Wall Street” when Bud Fox says “Life all comes down to a few moments. This is one of them”.

Some of us could make some real money this year if IHL keeps performing.

I just finished reading a very positive clinical paper from the American Journal of Epidemiology which evaluated early outpatient treatment of symptomatic, high risk Covid patients using HCQ.

IHL Price at posting: 5.4¢ Sentiment: Buy Disclosure: Held
9 Upvote

2 Great analysis

Reply

Top Stories

FEG

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

ADH

Adairs MD and CEO steps down after 17 years in company management

SRN

Copper and zinc zone prove exciting news for Surefire close to WA's Yidby

DEL

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

Is the ASX getting its groove back? Here's 5 IPOs in September to watch